Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, By Roots
To order this 310 page report, which features 110 figures and 200 tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html Key Inclusions uf0a7tA detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service(s) offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish), type of dosage form (solid and liquid), and installed capacity and batch size (if available). uf0a7tElaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market in North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its service portfolio, continuous manufacturing capabilities and facilities, recent developments and an informed future outlook. uf0a7tAn analysis of the various partnerships related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements), scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid). It also provides the regional distribution of the collaborations. uf0a7tAn analysis of the expansions related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion), geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid). uf0a7tAn estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites). The study examines the distribution of capacity, based on the type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of manufacturing facilities (North America, Europe and Asia-Pacific). uf0a7tA study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019, highlighting multiple parameters, such as year of award, type of grant, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers. uf0a7tAn in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019. It includes information on key parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio). It also features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach), as well as a patent benchmarking and a detailed valuation analysis. uf0a7tInitiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects. uf0a7tA review of the companies offering modular facilities / modular cleanrooms, with information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), year of establishment, company size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on the recent projects undertaken / executed by the companies providing modular facilities. uf0a7tA case study of the companies offering technologies / equipment (continuous blenders and mixers, continuous granulators, continuous dryers, continuous compressors, continuous coaters, flow reactors, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manufacturing process, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided. uf0a7tA case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: uf0a7tPurpose of Manufacturing uf0a7tIn-House uf0a7tContract service uf0a7tScale of Operation uf0a7tCommercial uf0a7tPreclinical / Clinical uf0a7tType of Continuous Manufacturing related Service uf0a7tAPI Manufacturing uf0a7tEnd Product manufacturing uf0a7tType of Drug Molecule uf0a7tBiologic uf0a7tSmall Molecule uf0a7tType of dosage form uf0a7tSolid uf0a7tLiquid uf0a7tKey Geographical Regions uf0a7tNorth America uf0a7tEurope uf0a7tAsia Pacific uf0a7tTranscripts of interviews held with the following senior level representatives of stakeholder companies uf0a7tAndrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies uf0a7tBayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals uf0a7tNick Thomson, Senior Director Chemical Research and Development, Pfizer uf0a7tHimanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences uf0a7tEric Fang, Chief Scientific Officer, Snapdragon Chemistry) uf0a7tIan Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde To request sample pages, please visit this - https://www.rootsanalysis.com/reports/312/request-sample.html Key Questions Answered uf0a7tWho are the key players engaged in continuous manufacturing of small molecules and biologics? uf0a7tWhat is the installed, global capacity for continuous manufacturing? uf0a7tWhat are the key growth drivers within this domain? uf0a7tWhat are the various paths to evolution within this industry? uf0a7tWho are the other key stakeholders (modular facility providers and technology / equipment developers) in this domain? uf0a7tHow is the current and future market opportunity likely to be distributed across key market segments? You may also be interested in the following titles: 1.tPharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028 2.tBiopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030 3.tChina Pharmaceutical Contract Manufacturing Services Market, 2020-2030 4.tChina Biopharmaceutical Contract Manufacturing Market, 2020 - 2030 Contact Us Gaurav Chaudhary 1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
27 views • 1 slides
